GT Biopharma, Inc. (GTBP)

GT Biopharma, Inc. (GTBP) Healthcare & Pipeline Overview

GT Biopharma, Inc. pioneers immuno-oncology with its TriKE platform, targeting cancers like AML and solid tumors. Their clinical-stage development focuses on GTB-3550 and preclinical programs like GTB-3650 and GTB-5550, positioning them in the competitive biotechnology sector with a market cap of $5.26M.

What Is the Investment Thesis for GTBP?

GT Biopharma, Inc. presents a high-risk, high-reward investment opportunity within the immuno-oncology space. The company's value hinges on the successful development and commercialization of its TriKE platform, particularly GTB-3550, currently in Phase I/II trials. Positive clinical data from these trials would serve as a major catalyst, potentially driving significant stock appreciation. The company's partnerships with Altor BioScience and the University of Minnesota provide validation and access to further innovation. However, the company faces significant challenges, including limited financial resources (market cap of $5.26M), dependence on clinical trial outcomes, and competition from larger, more established biotechnology companies. The company's small size (1 employee) also raises concerns about operational capacity. Investors should carefully weigh the potential upside against the substantial risks associated with clinical-stage biopharmaceutical companies before investing.

Based on FMP financials and quantitative analysis

GTBP Key Highlights

• GT Biopharma is focused on immuno-oncology with its TriKE fusion protein technology platform.
• GTB-3550 is in Phase I/II clinical trial for myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia, advanced systemic mastocytosis, and CD33+ malignancies.
• GTB-3650 is in preclinical studies targeting CD33 on the surface of myeloid leukemias.
• GTB-5550 is in preclinical studies for treating patients with B7-H3 positive solid tumors.
• The company has a co-development partnership agreement with Altor BioScience Corporation and a license agreement with the Regents of the University of Minnesota.

Who Are GTBP's Competitors?

GTBP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GTBP's Key Strengths?

• Proprietary TriKE technology platform.
• Clinical-stage asset (GTB-3550) with promising early results.
• Strategic partnerships with Altor BioScience and the University of Minnesota.
• Focus on unmet medical needs in cancer treatment.

What Are GTBP's Weaknesses?

• Limited financial resources (market cap of $5.26M).
• Dependence on clinical trial outcomes.
• Small company size (1 employee) limits operational capacity.
• High cash burn rate typical of clinical-stage biopharmaceutical companies.

What Could Drive GTBP Stock Higher?

• Interim data readout from the Phase I/II clinical trial of GTB-3550 in myelodysplastic syndromes and acute myeloid leukemia.
• Initiation of clinical trials for GTB-3650 targeting CD33 on myeloid leukemias.
• Announcement of new strategic partnerships or licensing agreements.
• Continued progress in preclinical development of GTB-5550 for B7-H3 positive solid tumors.

What Are the Key Risks for GTBP?

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to obtain positive results from clinical trials of GTB-3550.
• Delays in clinical trial timelines due to regulatory hurdles or patient enrollment challenges.
• Competition from larger pharmaceutical companies with more resources.
• Difficulty in raising capital to fund ongoing research and development.
• Intellectual property challenges or patent disputes.

What Are the Growth Opportunities for GTBP?

• Expansion of GTB-3550 Clinical Trials: GT Biopharma has the opportunity to expand the clinical trials for GTB-3550 beyond the current Phase I/II study. Positive results could lead to larger, pivotal trials and eventual FDA approval, addressing a significant unmet need in the treatment of myelodysplastic syndromes and acute myeloid leukemia. The market for AML treatments is projected to reach billions of dollars by 2030, offering a substantial revenue opportunity for GT Biopharma if GTB-3550 proves successful. This expansion could occur within the next 2-3 years.
• Advancement of GTB-3650 and GTB-5550: The preclinical programs, GTB-3650 and GTB-5550, represent significant growth opportunities for GT Biopharma. Successful completion of preclinical studies and subsequent entry into clinical trials could expand the company's pipeline and address additional cancer indications. The market for solid tumor therapies, targeted by GTB-5550, is particularly large and growing, offering substantial potential revenue. These programs could enter clinical trials within the next 3-5 years.
• Strategic Partnerships and Licensing Agreements: GT Biopharma can pursue additional strategic partnerships and licensing agreements to expand its TriKE technology platform and accelerate the development and commercialization of its products. Collaborations with larger pharmaceutical companies could provide access to funding, expertise, and distribution channels, increasing the likelihood of success. These partnerships could be established within the next 1-2 years.
• Expansion into New Cancer Indications: GT Biopharma has the potential to expand its TriKE technology platform into new cancer indications beyond its current focus. The platform's versatility allows for the development of TriKE molecules targeting a wide range of cancer antigens, opening up opportunities to address unmet needs in various cancer types. This expansion could begin within the next 3-5 years, following successful clinical trials of existing programs.
• Orphan Drug Designation and Accelerated Approval Pathways: GT Biopharma can leverage orphan drug designation and accelerated approval pathways to expedite the development and commercialization of its products. These regulatory mechanisms provide incentives and advantages for companies developing treatments for rare diseases, potentially shortening the time to market and increasing the likelihood of regulatory approval. The company should actively pursue these pathways for its lead product candidates.

What Opportunities Does GTBP Have?

• Expansion of GTB-3550 clinical trials into larger patient populations.
• Advancement of GTB-3650 and GTB-5550 into clinical development.
• Out-licensing or co-development agreements with larger pharmaceutical companies.
• Expansion of TriKE platform into new cancer indications.

What Threats Does GTBP Face?

• Clinical trial failures or delays.
• Competition from larger, more established biotechnology companies.
• Regulatory hurdles and delays in obtaining FDA approval.
• Difficulty in raising capital to fund ongoing research and development.

What Are GTBP's Competitive Advantages?

• Proprietary TriKE technology platform: This platform is protected by patents and provides a unique approach to cancer immunotherapy.
• Clinical-stage pipeline: GTB-3550 is in Phase I/II clinical trials, providing a potential first-mover advantage in certain indications.
• Strategic partnerships: Collaborations with Altor BioScience and the University of Minnesota provide access to expertise and resources.
• Focus on unmet needs: GT Biopharma is targeting cancers with limited treatment options, offering the potential for significant market penetration.

What Does GTBP Do?

GT Biopharma, Inc., founded in 1965 and formerly known as OXIS International, Inc., transitioned to its current focus in July 2017. The company is dedicated to the development and commercialization of innovative immuno-oncology products, leveraging its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. This platform is designed to harness the body's natural immune system to target and eliminate cancer cells. GT Biopharma's lead product candidate, GTB-3550, is currently in Phase I/II clinical trials for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia (AML), advanced systemic mastocytosis, and CD33+ malignancies. The company is also advancing GTB-3650 and GTB-5550, which are in preclinical studies targeting CD33 on myeloid leukemias and B7-H3 positive solid tumors, respectively. GT Biopharma has established strategic partnerships, including a co-development agreement with Altor BioScience Corporation for a 161533 TriKE fusion protein and a license agreement with the Regents of the University of Minnesota for TriKE technology development. Based in Brisbane, California, GT Biopharma is committed to transforming cancer therapy through its innovative TriKE platform.

What Products and Services Does GTBP Offer?

• Develops immuno-oncology products using the TriKE platform.
• Focuses on treatments for hematological malignancies and solid tumors.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Partners with other companies and institutions to advance its research and development efforts.
• Seeks regulatory approval for its products from agencies like the FDA.
• Aims to commercialize its products and make them available to patients in need.

How Does GTBP Make Money?

• Develops and patents novel TriKE-based immunotherapies.
• Out-licenses or co-develops its technologies with pharmaceutical partners.
• Generates revenue through milestone payments, royalties, and potential product sales.
• Focuses on research and development, with potential for future manufacturing and commercialization.

What Industry Does GTBP Operate In?

GT Biopharma operates within the competitive and rapidly evolving biotechnology industry, specifically in the immuno-oncology segment. This segment is characterized by high growth potential, driven by increasing cancer prevalence and the demand for more effective and targeted therapies. The market is dominated by large pharmaceutical companies and specialized biotechnology firms, all vying for market share with innovative approaches like cell therapies, checkpoint inhibitors, and targeted antibodies. GT Biopharma's TriKE technology represents a novel approach to cancer immunotherapy, potentially offering advantages in terms of efficacy and safety compared to existing treatments. However, the company faces significant competition and must navigate a complex regulatory landscape to successfully commercialize its products.

Who Are GTBP's Key Customers?

• Pharmaceutical companies seeking novel immuno-oncology therapies.
• Hospitals and cancer centers that treat patients with hematological malignancies and solid tumors.
• Patients with myelodysplastic syndromes, acute myeloid leukemia, and other cancers.
• Research institutions interested in collaborating on TriKE technology development.

FY2026 estForward Outlook

Wall Street analysts project GT Biopharma, Inc. revenue of about $9.7M for fiscal 2026, with EPS near $-0.34.

F-Score 2/9Financial Health

GT Biopharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

GT Biopharma, Inc. (GTBP) Valuation Context

Valued at $5.26M, GTBP is classified as a micro-cap stock. Relative to its peer group, GTBP's quantitative score of 28/100 is below the peer average of 76/100.

GTBP Financials

GTBP Latest News

GTBP Analyst Consensus

GTBP MoonshotScore

GT Biopharma, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources